

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 1, 2019**

**Aethlon Medical, Inc.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**001-37487**  
(Commission File Number)

**13-3632859**  
(IRS Employer Identification No.)

**9635 Granite Ridge Drive, Suite 100**  
**San Diego, California**  
(Address of principal executive offices)

**92123**  
(Zip Code)

**Registrant's telephone number, including area code: 858-459-7800**

Not applicable  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol | Name of each exchange on which registered |
|---------------------|----------------|---|
| Common Stock        | AEMD           | The Nasdaq Capital Market                 |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

On November 1, 2019, Aethlon Medical, Inc. (the “Registrant”) issued a press release announcing its financial results for the second quarter ended September 30, 2019. A copy of the press release is attached hereto as Exhibit 99.1.

The information provided in this Item 2.02 of this Current Report on Form 8-K, including the exhibits, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

| <u>Exhibit No.</u> | <u>Description</u>  |
|--------------------|---|
| 99.1               | <a href="#">Press Release of the Registrant dated November 1, 2019.</a> |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Aethlon Medical, Inc.**

Dated: November 1, 2019

By: /s/ James B. Frakes  
James B. Frakes  
Chief Financial Officer



## **Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update**

SAN DIEGO, CA, November 1, 2019 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its second quarter ended September 30, 2019 and provided an update on recent developments.

### **Company Updates**

Aethlon Medical, Inc. (Company or Aethlon) is continuing the development of its proprietary Hemopurifier, which is a first in class therapeutic device designed for the single use depletion of cancer-promoting exosomes and circulating viruses. The Hemopurifier has previously been designated a Breakthrough Device by the FDA for the treatment of glycosylated viruses, including Ebola and other hemorrhagic fever viruses, and in late 2018 was additionally designated as a Breakthrough Device "...for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease....".

Aethlon is currently preparing for the initiation of clinical trials in patients with advanced and metastatic cancers. The Company is initially focused on the treatment of solid tumors, including head and neck cancer, gastrointestinal cancers and other cancers. In September 2019, the Company filed an Investigational Device Exemption (IDE) application to support an initial Early Feasibility Study (EFS) in patients with advanced and/or metastatic head and neck cancer, which was approved by FDA on October 4, 2019 subject to submission of a final patient informed consent form. The Company is currently preparing to initiate a 10 to 12 subject EFS in patients with advanced and/or metastatic head and neck cancer. The EFS will be performed at a major academic research center to investigate the combination of the Hemopurifier with standard of care pembrolizumab (Keytruda®).

Through the Company's majority owned subsidiary, Exosome Sciences, Inc., a collaboration was recently initiated with Hoag Hospital Systems of Newport Beach, California to identify exosomal liquid biopsy markers in patients with, and at risk for, pancreas and other cancers. In addition, on September 12, 2019, Aethlon was awarded a \$1.86 million Phase II contract from the National Cancer Institute (NCI) under the Small Business Innovative Research (SBIR) program to develop a benchtop instrument to isolate and characterize exosomes in cancer. This award followed on the successful completion of a Phase I program that was completed in June 2018.

## Financial Results for Second Quarter Ended September 30, 2019

The Company's net loss was approximately \$1.7 million, or \$(1.29) per share, for the second quarter ended September 30, 2019, compared to a net loss of approximately \$1.4 million, or \$(1.17) per share, for the quarter ended September 30, 2018.

The Company's consolidated operating expenses for the quarter ended September 30, 2019 were approximately \$1.70 million, compared to approximately \$1.35 million for the quarter ended September 30, 2018. The increase of approximately \$350,000 in 2019 was due to increases in professional fees of \$360,000 and in general and administrative expenses of \$71,000, which were partially offset by a decrease in payroll and related expenses of \$75,000.

The \$360,000 increase in professional fees in 2019 was primarily due to a \$279,000 increase in legal fees, a \$69,000 increase in accounting fees and a \$65,000 payment to the University of Pittsburgh, a subcontractor on our SBIR breast cancer grant related to their work on that grant. The increase in legal and accounting fees related to increased activity in our registration statement filings and in intellectual property actions, among other matters.

The \$71,000 increase in general and administrative expenses in 2019 was primarily due to the combination of a \$21,000 increase in our clinical trial expense, primarily costs associated with the manufacturing of Hemopurifiers for an expected clinical trial in the cancer space, and a \$45,000 increase in our lab supplies expense, primarily related to the SBIR breast cancer grant and lab work related to the IDE application.

The \$75,000 decrease in payroll and related expenses in the quarter ended September 30, 2019 was due to the combination of a \$65,000 reduction in our cash-based compensation expense and a \$10,000 decrease in stock-based compensation compared the same period in 2018.

Other expense during the three months ended September 30, 2019 consisted of interest expense and a loss on share for warrant exchanges and during the three months ended September 30, 2018, consisted of interest expense only. Other expense for the three months ended September 30, 2019 was approximately \$4,400, in comparison with other expense of approximately \$55,000 for the three months ended September 30, 2018.

At September 30, 2019, the Company had a cash balance of approximately \$800,000. Since September 30, 2019, Company has raised approximately \$473,000 under its at-the-market facility and billed the NCI for approximately \$207,000 under our Phase 2 Melanoma Cancer Contract with the NCI.

On October 29, 2019, Nasdaq notified the Company that it has regained compliance with Nasdaq's minimum bid price continued listing requirement.

The unaudited condensed consolidated balance sheet for September 30, 2019 and the unaudited condensed consolidated statements of operations for the three and six months ended September 30, 2019 and 2018 follow at the end of this release.

## **Conference Call**

The Company will hold a conference call today, Friday, November 1, 2019 at 4:30 p.m. Eastern Time to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442. All callers should ask for the Aethlon Medical, Inc. conference call.

A replay of the call will be available approximately one hour after the end of the call through November 8, 2019. The replay can be accessed via Aethlon's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10136640.

## **About Aethlon and the Hemopurifier®**

Aethlon is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier depletes the presence of circulating tumor-derived exosomes that promote immune suppression.

These tumor derived exosomes also seed the spread of metastases and inhibit the benefit of leading cancer therapies. The Hemopurifier® is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.

Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at [www.AethlonMedical.com](http://www.AethlonMedical.com) and [www.ExosomeSciences.com](http://www.ExosomeSciences.com).

## Forward Looking Statements

*This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional funds, its ability meet and maintain the minimum stockholders' equity requirements and to maintain the minimum bid price requirement of the Nasdaq Capital Market, or any other national securities exchange, the Company's ability to successfully complete the Company's planned studies with its Hemopurifier or that Exosome Sciences' Inc.'s collaboration with Hoag Hospital Systems will be successful, and other potential products and other risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2019, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.*

## Company Contact:

Jim Frakes, CFO  
jfrakes@aethlonmedical.com  
858-459-7800 extension 3300

**AETHLON MEDICAL, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Balance Sheet**

|  | <b>September 30, 2019</b> | <b>March 31, 2019</b> |
|--|---------------------------|-----------------------|
| <b>ASSETS</b>  |                           |                       |
| <b>CURRENT ASSETS</b>  |                           |                       |
| Cash   | \$ 785,658                | \$ 3,828,074          |
| Prepaid expenses   | 114,036                   | 210,042               |
| <b>TOTAL CURRENT ASSETS</b>  | <b>899,694</b>            | <b>4,038,116</b>      |
| Property and equipment, net  | 124,833                   | 6,021                 |
| Right-of-use asset   | 183,018                   | –                     |
| Patents, net   | 62,086                    | 66,668                |
| Deposits   | 12,159                    | 12,159                |
| <b>TOTAL NONCURRENT ASSETS</b>   | <b>382,096</b>            | <b>84,848</b>         |
| <b>TOTAL ASSETS</b>  | <b>\$ 1,281,790</b>       | <b>\$ 4,122,964</b>   |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>  |                           |                       |
| <b>CURRENT LIABILITIES</b>   |                           |                       |
| Accounts payable   | 586,960                   | 131,931               |
| Due to related parties   | 101,462                   | 83,654                |
| Convertible notes payable, net   | –                         | 962,301               |
| Lease liability, current portion   | 94,885                    | –                     |
| Deferred revenue   | 100,000                   | –                     |
| Other current liabilities  | 285,211                   | 646,000               |
| <b>TOTAL CURRENT LIABILITIES</b>   | <b>1,168,518</b>          | <b>1,823,886</b>      |
| <b>NONCURRENT LIABILITIES</b>  |                           |                       |
| Lease liability, less current portion  | 92,600                    | –                     |
| <b>TOTAL NONCURRENT LIABILITIES</b>  | <b>92,600</b>             | <b>–</b>              |
| <b>TOTAL LIABILITIES</b>   | <b>1,261,118</b>          | <b>1,823,886</b>      |
| <b>COMMITMENTS AND CONTINGENCIES</b>   |                           |                       |
| <b>EQUITY</b>  |                           |                       |
| Common stock, par value of \$0.001, 30,000,000 shares authorized; 1,337,259 and 1,266,979 issued and outstanding | 1,338                     | 19,004                |
| Additional-paid in capital   | 109,571,708               | 108,058,538           |
| Accumulated deficit  | (109,423,894)             | (105,652,433)         |
| <b>TOTAL STOCKHOLDERS' EQUITY BEFORE NONCONTROLLING INTERESTS</b>  | <b>149,152</b>            | <b>2,425,109</b>      |
| Noncontrolling interests   | (128,480)                 | (126,031)             |
| <b>TOTAL STOCKHOLDERS' EQUITY</b>  | <b>20,672</b>             | <b>2,299,078</b>      |
| <b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>  | <b>\$ 1,281,790</b>       | <b>\$ 4,122,964</b>   |



**AETHLON MEDICAL, INC. AND SUBSIDIARIES**  
**Condensed Consolidated Statements of Operations**  
**For the three and six month periods ended June 30, 2019 and 2018**

|   | <u>Three Months</u><br><u>Ended 9/30/19</u> | <u>Three Months</u><br><u>Ended 9/30/18</u> | <u>Six Months</u><br><u>Ended 9/30/19</u> | <u>Six Months</u><br><u>Ended 9/30/18</u> |
|---|---|---|---|---|
| Government contract revenue   | \$ —  | \$ —  | \$ 30,000                                 | \$ 149,625                                |
| <b>OPERATING COSTS AND EXPENSES</b>                                   |   |   |   |   |
| Professional fees   | 762,337                                     | 403,044                                     | 1,369,915                                 | 852,479                                   |
| Payroll and related   | 597,526                                     | 672,279                                     | 1,203,521                                 | 1,274,844                                 |
| General and administrative  | 342,339                                     | 271,631                                     | 724,955                                   | 466,528                                   |
|   | <u>1,702,202</u>                            | <u>1,346,954</u>                            | <u>3,298,391</u>                          | <u>2,593,851</u>                          |
| <b>OPERATING LOSS</b>   | <b>(1,702,202)</b>                          | <b>(1,346,954)</b>                          | <b>(3,268,391)</b>                        | <b>(2,444,226)</b>                        |
| <b>OTHER (INCOME) EXPENSE</b>   |   |   |   |   |
| Loss on debt extinguishment   | —   | —   | 447,011                                   | —   |
| Loss on share for warrant exchanges                                   | 4,403                                       | —   | 4,403                                     | —   |
| Interest and other debt expenses                                      | 21  | 55,106                                      | 54,106                                    | 110,210                                   |
|   | <u>4,424</u>                                | <u>55,106</u>                               | <u>505,520</u>                            | <u>110,210</u>                            |
| <b>NET LOSS</b>   | <b>\$ (1,706,626)</b>                       | <b>\$ (1,402,060)</b>                       | <b>\$ (3,773,911)</b>                     | <b>\$ (2,554,436)</b>                     |
| Loss attributable to noncontrolling interests                         | <u>(1,589)</u>                              | <u>(8,715)</u>                              | <u>(2,450)</u>                            | <u>(14,864)</u>                           |
| <b>NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.</b>                 | <b>\$ (1,705,037)</b>                       | <b>\$ (1,393,345)</b>                       | <b>\$ (3,771,461)</b>                     | <b>\$ (2,539,572)</b>                     |
| Basic and diluted net loss available to common stockholders per share | <u>\$ (1.29)</u>                            | <u>\$ (1.17)</u>                            | <u>\$ (2.91)</u>                          | <u>\$ (2.14)</u>                          |
| Weighted average number of common shares outstanding                  | <u>1,317,418</u>                            | <u>1,185,949</u>                            | <u>1,294,206</u>                          | <u>1,184,795</u>                          |